Skip to content

EPIRUS Biopharmaceuticals, Inc.

CIK 0001135906

← back to feed
Revenue (TTM)
$10.03M
+10.8% YoY Q1 May 2016
Net Income (TTM)
−$53.06M
−24.7% YoY Q1 May 2016
EPS Diluted (TTM)
—
Q1 May 2016
Gross Margin
98.8%
Q1 May 2016
Operating Margin
-521.5%
Q1 May 2016
Net Margin
-529.2%
Q1 May 2016
Free Cash Flow (TTM)
−$34.45M
Q1 May 2016
Cash
$20.87M
Q1 May 2016
Total Debt
$27.42M
Q1 May 2016
Shares Outstanding
26.18M sh
Q1 May 2016

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings